Lipitor OTC Switch Would Force Pfizer To Clear Big Research Hurdles
This article was originally published in The Tan Sheet
Executive Summary
Pfizer would face major hurdles in research on consumers’ safe self-selection for FDA to approve an OTC switch of the firm’s cholesterol treatment Lipitor.